10549-59-4

Basic information

• Product Name: DIMETHYLETHANOLAMINESUCCINATE
• Synonyms: DIMETHYLETHANOLAMINESUCCINATE;Mono[2-(dimethylamino)ethyl] succinate;Tonibral;4-[2-(dimethylamino)ethoxy]-4-oxobutanoic acid
• CAS NO: 10549-59-4
• Molecular Formula: C₈H₁₅NO₄
• Molecular Weight: 189.21
• Mol File: 10549-59-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 78℃
• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Methanol
• CAS DataBase Reference: DIMETHYLETHANOLAMINESUCCINATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIMETHYLETHANOLAMINESUCCINATE(10549-59-4)
• EPA Substance Registry System: DIMETHYLETHANOLAMINESUCCINATE(10549-59-4)

Safety Data

• Hazardous Substances Data: 10549-59-4(Hazardous Substances Data)

Usage

Description

DIMETHYLETHANOLAMINESUCCINATE, also known as Tonibral, is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which allows it to participate in a range of chemical reactions and contribute to the development of novel therapeutic agents.

Uses

Used in Pharmaceutical Synthesis:
DIMETHYLETHANOLAMINESUCCINATE is used as an intermediate in the synthesis of Succinyl Monocholine Iodide (S688840), a compound with potential applications in the development of novel therapeutic agents.
Used in Drug Delivery Systems:
DIMETHYLETHANOLAMINESUCCINATE is used as a reagent in the synthesis of novel amphiphillic conjugates, which have the ability to recognize signals and exist as targeted liposomal delivery systems. These targeted delivery systems can improve the efficacy and specificity of drug treatments by ensuring that the therapeutic agents are delivered directly to the site of action, minimizing side effects and enhancing overall treatment outcomes.

InChI:InChI=1/C4H11NO.C4H6O4/c1-5(2)3-4-6;5-3(6)1-2-4(7)8/h6H,3-4H2,1-2H3;1-2H2,(H,5,6)(H,7,8)

Upstream product

• 108-30-5 succinic acid anhydride 
• 108-01-0 2-(N,N-dimethylamino)ethanol 

Relevant articles and documents

Synthesis and characterization of succinylcholine-d18 and succinylmonocholine-d3 designed for simultaneous use as internal standards in mass spectrometric analyses

Succinylcholine (SUX) is a routinely used yet potentially lethal depolarizing muscle relaxant, the detection of which poses severe problems to the clinical or forensic analyst: within a few minutes after its in vivo administration, SUX is broken down via succinylmonocholine (SMC) to yield the endogenous substances succinic acid and choline. For quantification of SUX and SMC in biological matrices using mass spectrometric detection, appropriate internal standards, i.e. deuterated analogs of the above substances, are indispensable but not commercially available. Internal standards for both substances were hence tailored to fit the analytical needs. The two-step synthesis and subsequent characterization of SUX-d18 and SMC-d 3 using a combination of nuclear magnetic resonance (NMR) spectroscopy, fast atom bombardment mass spectroscopy (FAB-MS) and high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) are described. SUX-d18 was synthesized by reacting ethanolamine and iodomethane-d3 in a first quaternization step to choline-d 9, which in turn was esterified with succinyldichloride to yield the final product. SMC-d3 was produced by esterification of succinic acid anhydride with dimethylaminoethanol, yielding desmethyl-SMC as intermediate product. The latter was then reacted with iodomethane-d3 to obtain SMC-d3. 1H- and 13C-NMR data support the identity and purity as well as the designated deuteration of both preparations, findings which were further confirmed by FAB-MS as well as HPLC-MS/MS. Owing to a thoughtful design, the obtained substances SUX-d18 and SMC-d 3 feature different deuteration patterns at their trimethylamine moieties, and thus finally offer the possibility to simultaneously quantify SUX and SMC in clinical as well as forensic samples using isotope dilution mass spectrometry. Copyright

Functional synthetic molecules and macromolecules for gene delivery

The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.